Exact Mass: 433.1822
Exact Mass Matches: 433.1822
Found 500 metabolites which its exact mass value is equals to given mass value 433.1822
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Meleagrine
An indole alkaloid with a heterotetracyclic skeleton isolated from Penicillium oxalicum.
8-[[(1R)-1-(3,4-Dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
Arg-gly-asp-ser
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
Sarpicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
8-((4-Amino-1-methylbutyl)amino)-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline
L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, (R)-
Fenfangjine G
(3,5-Isomer,6-oxo,N-Me-Gerambullin|Methylisogerambullone|methylisogerammbullone|MIGB
(1R)-(4-hydroxybenzyl)-7-hydroxyl-8-O-beta-D-glucopyranosyl-1,2,3,4-tetrahydroisoquinoline
6-Oxo,N-Me-Gerambullin|Methylgerambullone|methylgerammbullone
(-)-8alpha-(4-methoxybenzyl)-2-methoxyberbin-3,10,11-triol|(-)-8alpha-<4-methoxybenzyl>-2-methoxyberbin-3,10,11-triol|O4-Me-8-(4-Hydroxybenzyl)-2-methoxy-3,10,11-berbintriol
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
C23H23N5O4_(3Z)-6-Hydroxy-3-(1H-imidazol-5-ylmethylene)-12-methoxy-7a-(2-methyl-3-buten-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]
Ala Ala Ser Trp
Ala Ala Trp Ser
Ala Cys Ile Gln
Ala Cys Leu Gln
Ala Cys Gln Ile
Ala Cys Gln Leu
Ala Asp Gln Thr
Ala Asp Thr Gln
Ala Glu Asn Thr
Ala Glu Gln Ser
Ala Glu Ser Gln
Ala Glu Thr Asn
Ala Gly Thr Trp
Ala Gly Trp Thr
Ala Ile Cys Gln
Ala Ile Gln Cys
Ala Leu Cys Gln
Ala Leu Gln Cys
Ala Met Asn Val
Ala Met Val Asn
Ala Asn Glu Thr
Ala Asn Met Val
Ala Asn Thr Glu
Ala Asn Val Met
Ala Gln Cys Ile
Ala Gln Cys Leu
Ala Gln Asp Thr
Ala Gln Glu Ser
Ala Gln Ile Cys
Ala Gln Leu Cys
Ala Gln Ser Glu
Ala Gln Thr Asp
Ala Ser Ala Trp
Ala Ser Glu Gln
Ala Ser Gln Glu
Ala Ser Trp Ala
Ala Thr Asp Gln
Ala Thr Glu Asn
Ala Thr Gly Trp
Ala Thr Asn Glu
Ala Thr Gln Asp
Ala Thr Trp Gly
Ala Val Met Asn
Ala Val Asn Met
Ala Trp Ala Ser
Ala Trp Gly Thr
Ala Trp Ser Ala
Ala Trp Thr Gly
Cys Ala Ile Gln
Cys Ala Leu Gln
Cys Ala Gln Ile
Cys Ala Gln Leu
Cys Ile Ala Gln
Cys Ile Gln Ala
Cys Lys Pro Ser
Cys Lys Ser Pro
Cys Leu Ala Gln
Cys Leu Gln Ala
Cys Asn Val Val
Cys Pro Lys Ser
Cys Pro Ser Lys
Cys Gln Ala Ile
Cys Gln Ala Leu
Cys Gln Ile Ala
Cys Gln Leu Ala
Cys Ser Lys Pro
Cys Ser Pro Lys
Cys Val Asn Val
Cys Val Val Asn
Asp Ala Gln Thr
Asp Ala Thr Gln
Asp Asp Gly Lys
Asp Asp Lys Gly
Asp Gly Asp Lys
Asp Gly Lys Asp
Asp Gly Arg Ser
Asp Gly Ser Arg
Asp Lys Asp Gly
Asp Lys Gly Asp
Asp Asn Ser Val
Asp Asn Val Ser
Asp Gln Ala Thr
Asp Gln Thr Ala
Asp Arg Gly Ser
Asp Arg Ser Gly
Asp Ser Gly Arg
Asp Ser Asn Val
Asp Ser Arg Gly
Asp Ser Val Asn
Asp Thr Ala Gln
Asp Thr Gln Ala
Asp Val Asn Ser
Asp Val Ser Asn
Glu Ala Asn Thr
Glu Ala Gln Ser
Glu Ala Ser Gln
Glu Ala Thr Asn
Glu Gly Gln Thr
Glu Gly Thr Gln
Glu Asn Ala Thr
Glu Asn Thr Ala
Glu Gln Ala Ser
Glu Gln Gly Thr
Glu Gln Ser Ala
Glu Gln Thr Gly
Glu Ser Ala Gln
Glu Ser Gln Ala
Glu Thr Ala Asn
Glu Thr Gly Gln
Glu Thr Asn Ala
Glu Thr Gln Gly
Phe Gly Asn Pro
Phe Gly Pro Asn
Phe Asn Gly Pro
Phe Asn Pro Gly
Phe Pro Gly Asn
Phe Pro Asn Gly
Gly Ala Thr Trp
Gly Ala Trp Thr
Gly Asp Asp Lys
Gly Asp Lys Asp
Gly Asp Arg Ser
Gly Asp Ser Arg
Gly Glu Gln Thr
Gly Glu Thr Gln
Gly Phe Asn Pro
Gly Phe Pro Asn
Gly Ile Met Asn
Gly Ile Asn Met
Gly Lys Asp Asp
Gly Leu Met Asn
Gly Leu Asn Met
Gly Met Ile Asn
Gly Met Leu Asn
Gly Met Asn Ile
Gly Met Asn Leu
Gly Met Gln Val
Gly Met Val Gln
Gly Asn Phe Pro
Gly Asn Ile Met
Gly Asn Leu Met
Gly Asn Met Ile
Gly Asn Met Leu
Gly Asn Pro Phe
Gly Pro Phe Asn
Gly Pro Asn Phe
Gly Gln Glu Thr
Gly Gln Met Val
Gly Gln Thr Glu
Gly Gln Val Met
Gly Arg Asp Ser
Gly Arg Ser Asp
Gly Ser Asp Arg
Gly Ser Arg Asp
Gly Thr Ala Trp
Gly Thr Glu Gln
Gly Thr Gln Glu
Gly Thr Trp Ala
Gly Val Met Gln
Gly Val Gln Met
Gly Trp Ala Thr
Gly Trp Thr Ala
Ile Ala Cys Gln
Ile Ala Gln Cys
Ile Cys Ala Gln
Ile Cys Gln Ala
Ile Gly Met Asn
Ile Gly Asn Met
Ile Met Gly Asn
Ile Met Asn Gly
Ile Asn Gly Met
Ile Asn Met Gly
Ile Gln Ala Cys
Ile Gln Cys Ala
Lys Cys Pro Ser
Lys Cys Ser Pro
Lys Asp Asp Gly
Lys Asp Gly Asp
Lys Gly Asp Asp
Lys Pro Cys Ser
Lys Pro Ser Cys
Lys Ser Cys Pro
Lys Ser Pro Cys
Leu Ala Cys Gln
Leu Ala Gln Cys
Leu Cys Ala Gln
Leu Cys Gln Ala
Leu Gly Met Asn
Leu Gly Asn Met
Leu Met Gly Asn
Leu Met Asn Gly
Leu Asn Met Gly
Leu Gln Ala Cys
Leu Gln Cys Ala
Met Ala Asn Val
Met Ala Val Asn
Met Gly Ile Asn
Met Gly Leu Asn
Met Gly Asn Ile
Met Gly Asn Leu
Met Gly Gln Val
Met Gly Val Gln
Met Ile Gly Asn
Met Ile Asn Gly
Met Leu Gly Asn
Met Leu Asn Gly
Met Asn Ala Val
Met Asn Gly Ile
Met Asn Gly Leu
Met Asn Ile Gly
Met Asn Leu Gly
Asn Ala Glu Thr
Asn Ala Thr Glu
Asn Asp Ser Val
Asn Asp Val Ser
Asn Glu Ala Thr
Asn Glu Thr Ala
Asn Phe Gly Pro
Asn Phe Pro Gly
Asn Gly Phe Pro
Asn Gly Pro Phe
Asn Pro Phe Gly
Asn Pro Gly Phe
Asn Ser Asp Val
Asn Ser Val Asp
Asn Thr Ala Glu
Asn Thr Glu Ala
Asn Val Asp Ser
Asn Val Ser Asp
Pro Phe Gly Asn
Pro Phe Asn Gly
Pro Gly Phe Asn
Pro Gly Asn Phe
Pro Asn Phe Gly
Pro Asn Gly Phe
Gln Ala Asp Thr
Gln Ala Glu Ser
Gln Ala Ser Glu
Gln Ala Thr Asp
Gln Cys Leu Ala
Gln Asp Ala Thr
Gln Asp Thr Ala
Gln Glu Ala Ser
Gln Glu Gly Thr
Gln Glu Ser Ala
Gln Glu Thr Gly
Gln Gly Glu Thr
Gln Gly Met Val
Gln Gly Thr Glu
Gln Gly Val Met
Gln Ile Ala Cys
Gln Ile Cys Ala
Gln Leu Ala Cys
Gln Leu Cys Ala
Gln Met Gly Val
Gln Met Val Gly
Gln Ser Ala Glu
Gln Ser Glu Ala
Gln Thr Ala Asp
Gln Thr Asp Ala
Gln Thr Glu Gly
Gln Thr Gly Glu
Gln Val Gly Met
Gln Val Met Gly
Arg Asp Gly Ser
Arg Asp Ser Gly
Arg Gly Asp Ser
Arg Gly Ser Asp
Arg Ser Asp Gly
Arg Ser Gly Asp
Ser Ala Ala Trp
Ser Ala Glu Gln
Ser Ala Gln Glu
Ser Ala Trp Ala
Ser Cys Lys Pro
Ser Cys Pro Lys
Ser Asp Gly Arg
Ser Asp Asn Val
Ser Asp Arg Gly
Ser Asp Val Asn
Ser Glu Ala Gln
Ser Glu Gln Ala
Ser Gly Asp Arg
Ser Gly Arg Asp
Ser Lys Cys Pro
Ser Lys Pro Cys
Ser Asn Asp Val
Ser Asn Val Asp
Ser Pro Cys Lys
Ser Pro Lys Cys
Ser Gln Ala Glu
Ser Gln Glu Ala
Ser Arg Asp Gly
Ser Arg Gly Asp
Ser Val Asp Asn
Ser Val Asn Asp
Ser Trp Ala Ala
Thr Ala Asp Gln
Thr Ala Glu Asn
Thr Ala Gly Trp
Thr Ala Asn Glu
Thr Ala Gln Asp
Thr Ala Trp Gly
Thr Asp Ala Gln
Thr Asp Gln Ala
Thr Glu Ala Asn
Thr Glu Gly Gln
Thr Glu Asn Ala
Thr Glu Gln Gly
Thr Gly Ala Trp
Thr Gly Glu Gln
Thr Gly Gln Glu
Thr Gly Trp Ala
Thr Asn Ala Glu
Thr Asn Glu Ala
Thr Gln Ala Asp
Thr Gln Asp Ala
Thr Gln Glu Gly
Thr Gln Gly Glu
Thr Trp Ala Gly
Thr Trp Gly Ala
Val Ala Met Asn
Val Ala Asn Met
Val Cys Asn Val
Val Cys Val Asn
Val Asp Asn Ser
Val Asp Ser Asn
Val Gly Met Gln
Val Gly Gln Met
Val Met Ala Asn
Val Met Gly Gln
Val Met Asn Ala
Val Met Gln Gly
Val Asn Ala Met
Val Asn Cys Val
Val Asn Asp Ser
Val Asn Met Ala
Val Asn Ser Asp
Val Asn Val Cys
Val Gln Gly Met
Val Gln Met Gly
Val Ser Asp Asn
Val Ser Asn Asp
Val Val Cys Asn
Val Val Asn Cys
Trp Ala Ala Ser
Trp Ala Gly Thr
Trp Ala Ser Ala
Trp Ala Thr Gly
Trp Gly Ala Thr
Trp Gly Thr Ala
Trp Ser Ala Ala
Trp Thr Ala Gly
Trp Thr Gly Ala
6-(methylamino)hexane-1,2,3,4,5-pentol,4-(2H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline
1H-Pyrazole-4-carboxamide,5-chloro-N-[2-[(3,7-dimethyl-2-quinolinyl)amino]ethyl]-3-methyl-1-phenyl-(9CI)
Sarpicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3-[[4-(diethylamino)phenyl]azo]-1,2-dimethyl-1H-indazolium methyl sulphate
Arg-Gly-Asp-Ser
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(4-fluorophenyl)-N-(3-pyridinylmethyl)- (9CI)
(5aS,10bR)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate,99e.e.
(5aR,10bS)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate
(S)-(4-(3-(BENZYLOXY)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-OXOPROPYL)PHENYL)BORONIC ACID
Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate
Fluvastatin sodium
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer?of Fluvastatin. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].
(3r,5s)-Fluvastatin sodium
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors (3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
N-(2,4-dimethoxyphenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide
5-[(3,4-Dimethoxyphenyl)-[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-methyl-6-thiazolo[3,2-b][1,2,4]triazolol
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
8-[[(1R)-1-(3,4-Dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
(3Z)-3-[(2E,4E,6R)-1-hydroxy-6-[(2S,7R,8R)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.02,4]decan-8-yl]-4-methylhepta-2,4-dienylidene]pyrrolidine-2,4-dione
(3E,7aS,12aR)-6-hydroxy-3-(1H-imidazol-4-ylmethylidene)-12-methoxy-7a-(2-methylbut-3-en-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
4-chloro-N-[2-(1H-indol-3-yl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)ethyl]benzamide
3-(3,4,5-Trimethoxyphenyl)propanoic acid [2-(3,5-dimethoxyanilino)-2-oxoethyl] ester
7-[(2-Chloro-6-fluorophenyl)methyl]-1,3-dimethyl-8-[(3-methyl-1-piperidinyl)methyl]purine-2,6-dione
2-[(5,5-dimethyl-6H-[1,2,4]triazolo[3,4-a]isoquinolin-3-yl)thio]-1-(4-phenyl-1-piperazinyl)ethanone
(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1R,9S,10S,11S)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
cyclobutyl-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
Fluvastatin (sodium)
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
Izilendustat
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1)[1][1].